#SwingTradingStrategy Parataxis Holdings acquires a majority stake in Bridge Biotherapeutics

According to BlockBeats, Parataxis Holdings LLC, a digital asset investment firm, has signed an official agreement to acquire a controlling stake in Bridge Biotherapeutics, Inc. through Parataxis Korea Fund I LLC and its affiliated companies. The investment amounts to 25 billion South Korean won. Upon completion of the transaction, the company intends to rename itself Parataxis Korea and continue listing on KOSDAQ. This agreement is subject to customary closing conditions, including shareholder approval.

This acquisition will establish a Bitcoin-focused reserve platform in the South Korean public market, backed by institutional investors with extensive experience in digital asset investment. As part of the transaction, Edward Chin, founder and CEO of Parataxis Holdings and co-founder and CEO of Parataxis Capital, will join the board of directors of the company. Andrew Kim, a partner at Parataxis Capital, will become the CEO of the company and also join the board of directors. James Jungkue Lee, co-founder of Bridge Bio, will continue to lead the core biotechnology sector and hold a seat on the board of directors.